Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.businesswire.com/news/home/20211101005515/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-IIb-Study-of-Its-Novel-PARP-Inhibitor-RP12146-in-Patients-With-Advanced-Solid-Tumors
https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients
https://www.businesswire.com/news/home/20211013005802/en/Rhizen-Pharmaceuticals-AG-Announces-First-Patient-Dosing-in-a-Phase-II-Study-of-Tenalisib-RP6530-in-Locally-Advanced-or-Metastatic-Breast-Cancer-Patients
https://www.clinicaltrialsarena.com/news/rhizen-oral-drug-trial-india/
https://www.businesstoday.in/sectors/pharma/first-new-chemical-entity-discovered-by-indian-scientists-gets-us-fda-approval/story/430693.html
https://www.thehindu.com/business/alembic-partners-anti-blood-cancer-drug-gets-us-fda-nod/article33795640.ece